Aficamten vs. Metoprolol for HCM; Beta Blocks and Myocardial Infarction (MI); Reconditioned Pacemakers for Improving Global CV Health
Échec de l'ajout au panier.
Veuillez réessayer plus tard
Échec de l'ajout à la liste d'envies.
Veuillez réessayer plus tard
Échec de la suppression de la liste d’envies.
Veuillez réessayer plus tard
Échec du suivi du balado
Ne plus suivre le balado a échoué
Aficamten vs. Metoprolol for HCM; Beta Blocks and Myocardial Infarction (MI); Reconditioned Pacemakers for Improving Global CV Health
-
Narrateur(s):
-
Auteur(s):
À propos de cet audio
In this week’s View, Dr. Eagle looks at major trials presented at the recent ESC Congress in Spain. First, he discusses the MAPLE-HCM trial that investigates aficamten versus metoprolol monotherapy in patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM). He then explores a set of important presentations on beta blocker therapy following myocardial infarction. Finally, Dr. Eagle talks about new research on the use of reconditioned pacemakers that shows promise for strengthening global cardiovascular health.
Subscribe to Eagle’s Eye View
Pas encore de commentaire